当前位置: 首页 >> 检索结果
161. Combined systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) predicts chemotherapy response and prognosis in locally advanced gastric cancer patients receiving neoadjuvant chemotherapy with PD-1 antibody sintilimab and XELOX: a prospective study.
作者: Ping'an Ding.;Honghai Guo.;Chenyu Sun.;Peigang Yang.;Na Hyun Kim.;Yuan Tian.;Yang Liu.;Pengpeng Liu.;Yong Li.;Qun Zhao.
来源: BMC Gastroenterol. 2022年22卷1期121页
Previous studies have confirmed that systemic immune-inflammatory index (SII) and prognostic nutritional index (PNI) can predict the prognosis and chemotherapy efficacy of various malignant tumors. However, to the best of our knowledge, no study investigated the SII combined with PNI score to predict the efficacy of anti-programmed death 1 (anti-PD-1) antibody sintilimab and XELOX regimen (capecitabine plus oxaliplatin) in the treatment of locally advanced gastric cancer. This study aims to evaluate the predictive value of pre-treatment SII-PNI score on the sensitivity of sintilimab immunotherapy combined with XELOX chemotherapy in patients with locally advanced gastric cancer.
162. A novel duodenal-release formulation of caraway oil and L-menthol is a safe, effective and well tolerated therapy for functional dyspepsia.
作者: Brian E Lacy.;William D Chey.;Michael S Epstein.;Syed M Shah.;Patrick Corsino.;Linda R Zeitzoff.;Brooks D Cash.
来源: BMC Gastroenterol. 2022年22卷1期105页
A randomized, placebo-controlled clinical trial (FDREST) of a novel formulation of caraway oil and L-menthol (COLM-SST) demonstrated symptom relief in patients with functional dyspepsia (FD). Two follow-up studies were conducted to evaluate patient satisfaction, self-regulated dosing, and long-term safety data: FDACT, Functional Dyspepsia Adherence and Compliance Trial, and FDSU36, Functional Dyspepsia Safety Update at 36 months.
163. Investigating the effect of quadruple therapy with Saccharomyces boulardii or Lactobacillus reuteri strain (DSMZ 17648) supplements on eradication of Helicobacter pylori and treatments adverse effects: a double-blind placebo-controlled randomized clinical trial.
作者: Nooshin Naghibzadeh.;Fatemeh Salmani.;Samira Nomiri.;Tahmine Tavakoli.
来源: BMC Gastroenterol. 2022年22卷1期107页
The goal of this study was to investigate the effects of treatment with Saccharomyces boulardii and Lactobacillus reuteri on the eradication of Helicobacter pylori and Adverse effects (AEs) of the treatment.
164. Administration of probiotics to healthy volunteers: effects on reactivity of intestinal mucosa and systemic leukocytes.
作者: Christina Stene.;Andrada Röme.;Ingrid Palmquist.;Caroline Linninge.;Göran Molin.;Siv Ahrné.;Louis Banka Johnson.;Bengt Jeppsson.
来源: BMC Gastroenterol. 2022年22卷1期100页
Oral administration of health-promoting bacteria is increasingly used in clinical practise. These bacteria have anti-inflammatory characteristics and modulate the immune system without major reported side effects. The mechanisms of action are not yet fully defined. Our aim was to study systemic effects of probiotics by measurements of leukocytes as well as local effects on rectal mucosal biopsies after adding a standardized inflammatory stimulus in vitro.
165. Impact of a procalcitonin-based algorithm on the quality of management of patients with uncomplicated adhesion-related small bowel obstruction assessed by a textbook outcome: a multicenter cluster-randomized open-label controlled trial.
作者: Charles Sabbagh.;Francois Mauvais.;Jean-Jacques Tuech.;Christophe Tresallet.;Pablo Ortega-Debalon.;Muriel Mathonnet.;Jeremie H Lefevre.;Zaher Lakkis.;David Fuks.;Fabrice Muscari.;Bernard Dron.;Philippe Couderc.;Arnaud Alves.;Jean-Marc Regimbeau.
来源: BMC Gastroenterol. 2022年22卷1期90页
Acute adhesion-related small bowel obstruction (ASBO) is a common digestive emergency, accounting for 1 to 3% of all digestive emergencies. The efficacy of conservative management in this setting is a subject of debate, as it may delay the decision to perform surgery and increase the frequency of bowel resection (e.g., in the presence of bowel necrosis) or, in contrast, prompt an excessive number of unnecessary laparotomies. Thus, the decision to perform surgery is difficult. We propose that the introduction of the procalcitonin (PCT)-based algorithm improves the quality of the management of patients with ASBO by aiding the decision of whether or not to perform surgery.
166. Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.
作者: Julián Panés.;Jean-Frederic Colombel.;Geert R D'Haens.;Stefan Schreiber.;Remo Panaccione.;Laurent Peyrin-Biroulet.;Edward V Loftus.;Silvio Danese.;Satoshi Tanida.;Yusuke Okuyama.;Edouard Louis.;Alessandro Armuzzi.;Marc Ferrante.;Harald Vogelsang.;Toshifumi Hibi.;Mamoru Watanabe.;Jessica Lefebvre.;Tricia Finney-Hayward.;Yuri Sanchez Gonzalez.;Thao T Doan.;Nael M Mostafa.;Kimitoshi Ikeda.;Wangang Xie.;Bidan Huang.;Joel Petersson.;Jasmina Kalabic.;Anne M Robinson.;William J Sandborn.
来源: Gastroenterology. 2022年162卷7期1891-1910页
SERENE UC (Study of a Novel Approach to Induction and Maintenance Dosing With Adalimumab in Patients With Moderate to Severe Ulcerative Colitis) evaluated the efficacy of higher adalimumab induction and maintenance dose regimens in patients with ulcerative colitis.
167. Effect of a 12-week home-based exercise training program on aerobic capacity, muscle mass, liver and spleen stiffness, and quality of life in cirrhotic patients: a randomized controlled clinical trial.
作者: Pavapol Sirisunhirun.;Wimolrak Bandidniyamanon.;Yonworanat Jrerattakon.;Kobkun Muangsomboon.;Pornpoj Pramyothin.;Supot Nimanong.;Tawesak Tanwandee.;Phunchai Charatcharoenwitthaya.;Siwaporn Chainuvati.;Watcharasak Chotiyaputta.
来源: BMC Gastroenterol. 2022年22卷1期66页
Physical inactivity and sarcopenia are two important predictors associated with increased morbidity and mortality in patients with cirrhosis. At present, the benefit of a home-based exercise training program is not well established in cirrhotic patients. The main objective of this study was to evaluate the effect of a 12-week home-based exercise training program on aerobic capacity in cirrhotic patients.
168. Development and validation of a model to predict rebleeding within three days after endoscopic hemostasis for high-risk peptic ulcer bleeding.
作者: Yongkang Lai.;Yuling Xu.;Zhenhua Zhu.;Xiaolin Pan.;Shunhua Long.;Wangdi Liao.;Bimin Li.;Yin Zhu.;Youxiang Chen.;Xu Shu.
来源: BMC Gastroenterol. 2022年22卷1期64页
Peptic ulcer bleeding remains a typical medical emergency with significant morbidity and mortality. Peptic ulcer rebleeding often occurs within three days after emergent endoscopic hemostasis. Our study aims to develop a nomogram to predict rebleeding within three days after emergent endoscopic hemostasis for high-risk peptic ulcer bleeding.
169. Endoscopic retrograde appendicitis therapy versus laparoscopic appendectomy versus open appendectomy for acute appendicitis: a pilot study.
作者: Zhemin Shen.;Peilong Sun.;Miao Jiang.;Zili Zhen.;Jingtian Liu.;Mu Ye.;Weida Huang.
来源: BMC Gastroenterol. 2022年22卷1期63页
An increasing number of studies have shown the merits of endoscopic retrograde appendicitis therapy (ERAT) in diagnosing and treating acute uncomplicated appendicitis. However, no related prospective controlled studies have been reported yet. Our aim is to assess the feasibility and safety of ERAT in the treatment of acute uncomplicated appendicitis.
170. Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study.
作者: William J Sandborn.;Geert R D'Haens.;Walter Reinisch.;Julián Panés.;Daphne Chan.;Susana Gonzalez.;Kathleen Weisel.;Matthew Germinaro.;Mary Ellen Frustaci.;Zijiang Yang.;Omoniyi J Adedokun.;Chenglong Han.;Remo Panaccione.;Tadakazu Hisamatsu.;Silvio Danese.;David T Rubin.;Bruce E Sands.;Anita Afzali.;Jane M Andrews.;Brian G Feagan.; .
来源: Gastroenterology. 2022年162卷6期1650-1664.e8页
Guselkumab, a selective p19 interleukin-23 antagonist, is approved for the treatment of plaque psoriasis and psoriatic arthritis. This study evaluated the efficacy and safety of guselkumab in patients with moderately to severely active Crohn's disease with inadequate response or intolerance to conventional or biologic therapy.
171. Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results.
作者: Geert R D'Haens.;William J Sandborn.;Edward V Loftus.;Stephen B Hanauer.;Stefan Schreiber.;Laurent Peyrin-Biroulet.;Remo Panaccione.;Julián Panés.;Filip Baert.;Jean-Frederic Colombel.;Marc Ferrante.;Edouard Louis.;Alessandro Armuzzi.;Qian Zhou.;Venkata S Goteti.;Nael M Mostafa.;Thao T Doan.;Joel Petersson.;Tricia Finney-Hayward.;Alexandra P Song.;Anne M Robinson.;Silvio Danese.
来源: Gastroenterology. 2022年162卷7期1876-1890页
Dose-optimization strategies for biologic therapies in Crohn's disease (CD) are not well established. The SERENE CD (Study of a Novel Approach to Induction and Maintenance Dosing With Adalimumab in Patients With Moderate to Severe Crohn's Disease) trial evaluated higher vs standard adalimumab induction dosing and clinically adjusted (CA) vs therapeutic drug monitoring (TDM) maintenance strategies in patients with moderately to severely active CD.
172. 1L NER1006 can improve rates of adequate and high-quality bowel cleansing in the right colon: a post hoc analysis of two randomised clinical trials.
作者: Jonathan Manning.;Juha Halonen.;Sandra Jose Cheriyamkunnel.;Marco Antonio Álvarez-González.
来源: BMC Gastroenterol. 2022年22卷1期35页
The right colon is difficult to cleanse compared with other colon segments. This post hoc analysis of two randomised clinical trials (MORA and NOCT) examined whether 1L polyethylene glycol (PEG) NER1006 and two mid-volume alternatives could improve adequate and high-quality cleansing in the right colon among patients with complete cleansing assessments.
173. Strategies for discontinuation of proton pump inhibitors (PPIs) in patients with long-term PPI administration: a randomized controlled trial.
作者: Mariko Hojo.;Daisuke Asaoka.;Yuji Shimada.;Shuko Nojiri.;Akihito Nagahara.
来源: BMC Gastroenterol. 2022年22卷1期21页
Proton pump inhibitors (PPIs), including potassium ion-competitive acid blocker, are widely used worldwide and are often used for long periods of time. However, in recent years, potential side effects associated with long-term PPI use have been reported. Many patients take PPI for a long period of time, even though it is unnecessary, and it is necessary to discontinue PPI administration in such patients. However, sudden discontinuation may cause symptoms to recur and discontinuation may be unsuccessful. A strategy for safe and secure PPI discontinuation has not yet been established. The purpose of this study is to determine whether PPI can be safely discontinued by tapering the PPI dose or by abrupt discontinuation of PPI, and to establish a strategy for safe and secure PPI discontinuation.
174. The effect of group-based education on gastrointestinal symptoms and quality of life in patients with celiac disease: randomized controlled clinical trial.
作者: Zahra Akbari Namvar.;Reza Mahdavi.;Masood Shirmohammadi.;Zeinab Nikniaz.
来源: BMC Gastroenterol. 2022年22卷1期18页
In this trial, we investigated the effect of a group-based education program on gastrointestinal (GI) symptoms and quality of life (QOL) in patients with celiac disease (CD).
175. Inhibition of Viral Replication Reduces Transcriptionally Active Distinct Hepatitis B Virus Integrations With Implications on Host Gene Dysregulation.
作者: Yao-Chun Hsu.;Vithika Suri.;Mindie H Nguyen.;Yen-Tsung Huang.;Chi-Yi Chen.;I-Wei Chang.;Cheng-Hao Tseng.;Chun-Ying Wu.;Jaw-Town Lin.;David Z Pan.;Anuj Gaggar.;Ondrej Podlaha.
来源: Gastroenterology. 2022年162卷4期1160-1170.e1页
Hepatocellular carcinogenesis of hepatitis B virus (HBV) infection may arise from integration of viral DNA into the host genome. We aimed to gauge the effect of viral inhibition on transcriptionally active HBV-host integration events and explore the correlation of viral integrations with host gene dysregulation.
176. Comparison of the innovative endoscopic oropharyngeal airway and the conventional mouthpiece in elderly outpatients undergoing esophagogastroduodenoscopy under sedation: a prospective and randomized study.
作者: Wei Zhang.;Chun Zhu.;Xu Chen.;Lei Tao.;Keqiang He.;Hao Wu.;Xiaoqing Chai.;Sheng Wang.;Min Xia.
来源: BMC Gastroenterol. 2022年22卷1期8页
Undesirable outcomes may appear for elderly patients undergoing esophagogastroduodenoscopy (EGD) under sedation, such as hypoxia and hypotension. The aim of our study was to investigate the ability of the innovative endoscopic oropharyngeal airway to reduce the frequency of hypoxia during EGD under sedation in elderly patients.
177. Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study.
作者: Fumitaka Suzuki.;Yoshiyuki Suzuki.;Yoshiyasu Karino.;Yasuhito Tanaka.;Masayuki Kurosaki.;Hiroshi Yatsuhashi.;Tomofumi Atarashi.;Masanori Atsukawa.;Tsunamasa Watanabe.;Masaru Enomoto.;Masatoshi Kudo.;Naoto Maeda.;Hiroshi Kohno.;Kouji Joko.;Kojiro Michitaka.;Koichiro Miki.;Kazuhiro Takahashi.;Tatsuya Ide.;Shigetoshi Fujiyama.;Tomoko Kohno.;Hiroshi Itoh.;Sakiyo Tsukamoto.;Yuko Suzuki.;Yoshiaki Kawano.;Wataru Sugiura.;Hiromitsu Kumada.
来源: BMC Gastroenterol. 2021年21卷1期489页
Tenofovir disoproxil fumarate (TDF) is widely used and recommended as first-line treatment for patients infected with the hepatitis B virus (HBV). However, current data are limited regarding the efficacy and safety of switching to TDF for the treatment of chronic hepatitis B in hepatitis B e-antigen (HBeAg)-positive patients who are virologically suppressed with another nucleos(t)ide analogue. The primary objective of this study was to evaluate the hepatitis B surface antigen (HBsAg) reduction potential of switching from entecavir (ETV) to TDF at week 48 in HBeAg-positive chronic hepatitis B patients with undetectable serum HBV-DNA.
178. Development and validation of a novel diagnostic model for initially clinical diagnosed gastrointestinal stromal tumors using an extreme gradient-boosting machine.
作者: Bozhi Hu.;Chao Wang.;Kewei Jiang.;Zhanlong Shen.;Xiaodong Yang.;Mujun Yin.;Bin Liang.;Qiwei Xie.;Yingjiang Ye.;Zhidong Gao.
来源: BMC Gastroenterol. 2021年21卷1期481页
Gastrointestinal stromal tumor (GIST) is the most common gastrointestinal soft tissue tumor. Clinical diagnosis mainly relies on enhanced CT, endoscopy and endoscopic ultrasound (EUS), but the misdiagnosis rate is still high without fine needle aspiration biopsy. We aim to develop a novel diagnostic model by analyzing the preoperative data of the patients.
179. Development and validation of the nomogram based on INR and eGFR for estimation of mortality in patients with acute-on-chronic hepatitis B liver failure.
作者: Shengnan Li.;Xiehua Zhang.;Qian Li.;Binyue Lv.;Yefan Zhang.;Jianwei Jia.;Xiaofen Yue.;Wei Lu.
来源: BMC Gastroenterol. 2021年21卷1期474页
Acute-on-chronic hepatitis B liver failure (ACHBLF) is a critical clinical syndrome with a high short-term mortality evolved from chronic hepatitis B (CHB)-related liver disease. Prediction of mortality risk and early intervention can improve the prognosis of patients. This study aimed to develop and validate the nomogram for short-time mortality estimation in ACHBLF patients defined according to Asian Pacific Association for the Study of the Liver (APASL).
180. Outcomes of endoscopic submucosal dissection for gastroesophageal reflux disease (ESD-G) for medication-refractory gastroesophageal reflux disease: 35 cases underwent ESD-G including 15 cases followed more than 5 years.
作者: Kazuhiro Ota.;Toshihisa Takeuchi.;Yuichi Kojima.;Noriaki Sugawara.;Shinya Nishida.;Taro Iwatsubo.;Shimpei Kawaguchi.;Satoshi Harada.;Satoshi Tokioka.;Kazuhide Higuchi.
来源: BMC Gastroenterol. 2021年21卷1期432页
Although some kinds of endoluminal surgery for patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD) have been reported, there are few reports on their long-term outcomes. In 2014, we reported the effectiveness of endoscopic surgery for PPI-refractory GERD, which we invented and named endoscopic submucosal dissection for GERD (ESD-G) in 2008. Thereafter, we accumulated more cases and monitored the patients' condition postoperatively and describe the outcomes herein.
|